Skip to content

Research on thrombolysis thrapy in acute ischemic stroke

Research on thrombolysis thrapy in acute ischemic stroke

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-10001745
Enrollment
Unknown
Registered
2010-08-15
Start date
2004-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

1:intravenous thrombolysis with Urokinase within 3h
2:intravenous thrombolysis with Urokinase within 3-6
3:intravenous thrombolysis with Urokinase within 6-9
4:intravenous thrombolysis with rtPA within 3h
5:intravenous thrombolysis with rtPA within 3-6h
6:intravenous thrombolysis with rtPA within 6-9h
7:intra-arterial thrombolysis with Urokinase within 3 hours
8:intra-arterial thrombolysis with Urokinase within 3-6 hours
9:intra-arterial thrombolysis with Urokinase within 6-9 hours
10:intra-arterial thrombolysis with rtPA within 3h
11:intra-arterial thrombolysis with rtPA within 3-6h
12:intra-arterial thrombolysis with rtPA within 3-6h

Sponsors

Xuanwu Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years; 2. Diagnosed as acute ischemic stroke and specific neurological deficits (NIHSS >4); 3. Onset to Intervention time <=9 hours; 4. Signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Evidence of intracranial hemorrhage on manifestation or CT; 2. Slight neurological deficits or coma or NIHSS >25; 3. Complicated with seizure; 4. Past history of intracranial hemorrhage, arteriovenous malformation or intracranial aneurysm,or trauma, surgery or active hemorrhage of internal organs,; 5. Inclination of bleeding: PLT normal upper limit, INR>1.5; 6. Blood pressure>180/100mmHg, Serum glucose 22.2mmol/L; 7. CT shows lower attenuation >1/3MCA area; 8. Complicated with severe hepatic, renal and other disease or other malignant tumor and survival<1 year; 9. Allergic to the contrast medium; 10. Without the informed consent signed.

Design outcomes

Primary

MeasureTime frame
Incidence rate of intracranial hemorrhage in 1 week;24h NIHSS scores;mRS =75 rate in the 3 month;

Countries

China

Contacts

Public ContactJianping Jia
jiajp.xw@gmail.com+86 13911052899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026